Plasma Circulating Tumor Epstein-Barr Virus for the Surveillance of Cancer Progression in Bone-Only Metastatic Nasopharyngeal Carcinoma.
EBV-DNA
bone-only metastasis
cancer progression
nasopharyngeal carcinoma
surveillance
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
01
2022
accepted:
18
04
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Plasma Epstein-Barr virus DNA (EBV-DNA) is a sensitive and specific biomarker for nasopharyngeal carcinoma (NPC). We investigated whether longitudinal monitoring of EBV-DNA could accurately detect clinical disease progression in NPC patients with bone-only metastases. In this retrospective study, a total of 105 patients with bone-only metastatic NPC who were treated with platinum-based first-line chemotherapy were enrolled. Undetectable EBV-DNA after first-line chemotherapy was defined as a biochemical complete response (BCR). The correlation of the EBV-DNA dynamic status with overall survival (OS) and progression-free survival (PFS) was determined by Cox regression. The correlation between non-normalized EBV-DNA period and PFS period was determined. After a median follow-up time of 53.4 months [Interquartile range (IQR): 42.8-80.6], 64 patients had disease progression. Thirty-nine of 105 patients (37.1%) had a BCR at all follow-up time points, and none of these 39 patients had disease progression, corresponding to a negative predictive value (NPV) of 100%. Sixty-six patients had a detectable EBV-DNA during surveillance, with 64 diagnosed as disease progression at the last follow-up, for a positive predictive value (PPV) of 97.0%. Actuarial 3-year OS rates were 45.0% for patients with detectable EBV-DNA during posttreatment surveillance and 100% for patients with undetectable EBV-DNA. Lastly, median lead time between non-normalized EBV-DNA and clinically proven progression was 5.87 ± 0.67 months. Taken together, EBV-DNA provided predictive value for the bone-only metastatic NPC patients. The results should be validated in prospective randomized studies.
Sections du résumé
Background
UNASSIGNED
Plasma Epstein-Barr virus DNA (EBV-DNA) is a sensitive and specific biomarker for nasopharyngeal carcinoma (NPC). We investigated whether longitudinal monitoring of EBV-DNA could accurately detect clinical disease progression in NPC patients with bone-only metastases.
Methods
UNASSIGNED
In this retrospective study, a total of 105 patients with bone-only metastatic NPC who were treated with platinum-based first-line chemotherapy were enrolled. Undetectable EBV-DNA after first-line chemotherapy was defined as a biochemical complete response (BCR). The correlation of the EBV-DNA dynamic status with overall survival (OS) and progression-free survival (PFS) was determined by Cox regression. The correlation between non-normalized EBV-DNA period and PFS period was determined.
Results
UNASSIGNED
After a median follow-up time of 53.4 months [Interquartile range (IQR): 42.8-80.6], 64 patients had disease progression. Thirty-nine of 105 patients (37.1%) had a BCR at all follow-up time points, and none of these 39 patients had disease progression, corresponding to a negative predictive value (NPV) of 100%. Sixty-six patients had a detectable EBV-DNA during surveillance, with 64 diagnosed as disease progression at the last follow-up, for a positive predictive value (PPV) of 97.0%. Actuarial 3-year OS rates were 45.0% for patients with detectable EBV-DNA during posttreatment surveillance and 100% for patients with undetectable EBV-DNA. Lastly, median lead time between non-normalized EBV-DNA and clinically proven progression was 5.87 ± 0.67 months.
Conclusions
UNASSIGNED
Taken together, EBV-DNA provided predictive value for the bone-only metastatic NPC patients. The results should be validated in prospective randomized studies.
Identifiants
pubmed: 35756638
doi: 10.3389/fonc.2022.860700
pmc: PMC9226300
doi:
Types de publication
Journal Article
Langues
eng
Pagination
860700Informations de copyright
Copyright © 2022 Liu, Xia, Bi, Lu, Li, Bei, Liang, Xie, Liu, Yao and Xiang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
JAMA Oncol. 2019 Aug 01;5(8):1124-1131
pubmed: 31070691
Ann Nucl Med. 2018 Jun;32(5):348-362
pubmed: 29667143
Lancet Oncol. 2009 Jun;10(6):606-14
pubmed: 19482249
J Clin Oncol. 2019 Jun 20;37(18):1547-1557
pubmed: 31059311
Lancet. 2016 Oct 15;388(10054):1883-1892
pubmed: 27567279
Cancer. 2011 Aug 15;117(16):3750-7
pubmed: 21319149
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1832-1844
pubmed: 28612079
Cancer Lett. 2016 Apr 28;374(1):22-30
pubmed: 26828135
Ann Oncol. 2015 Jun;26(6):1048-1057
pubmed: 25471332
Int J Cancer. 2005 Nov 10;117(3):515-6
pubmed: 15906350
Clin Cancer Res. 2010 Feb 1;16(3):1016-24
pubmed: 20103659
Lancet Oncol. 2004 Oct;5(10):607-16
pubmed: 15465464
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
J Natl Cancer Inst. 2015 Oct 14;108(1):
pubmed: 26467665
JAMA Oncol. 2020 Sep 1;6(9):1345-1352
pubmed: 32701129
JAMA Oncol. 2019 Aug 01;5(8):1118-1123
pubmed: 31070668
Nucl Med Mol Imaging. 2019 Aug;53(4):247-252
pubmed: 31456857
JAMA Oncol. 2020 Dec 23;:
pubmed: 33355642
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1873-1883
pubmed: 29766246